JP2016525548A - Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 - Google Patents

Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 Download PDF

Info

Publication number
JP2016525548A
JP2016525548A JP2016529872A JP2016529872A JP2016525548A JP 2016525548 A JP2016525548 A JP 2016525548A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016529872 A JP2016529872 A JP 2016529872A JP 2016525548 A JP2016525548 A JP 2016525548A
Authority
JP
Japan
Prior art keywords
desmopressin
administered
hours
adrenergic receptor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525548A5 (enExample
Inventor
シーモア エイチ ファイン
シーモア エイチ ファイン
サミュエ ヘルシュコヴィッツ
サミュエル ヘルシュコヴィッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016525548A publication Critical patent/JP2016525548A/ja
Publication of JP2016525548A5 publication Critical patent/JP2016525548A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2016529872A 2013-07-23 2014-07-23 Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物 Pending JP2016525548A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
US61/857,431 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065913A Division JP7219736B2 (ja) 2013-07-23 2020-04-01 Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Publications (2)

Publication Number Publication Date
JP2016525548A true JP2016525548A (ja) 2016-08-25
JP2016525548A5 JP2016525548A5 (enExample) 2017-08-31

Family

ID=51299056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529872A Pending JP2016525548A (ja) 2013-07-23 2014-07-23 Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2020065913A Active JP7219736B2 (ja) 2013-07-23 2020-04-01 Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020065913A Active JP7219736B2 (ja) 2013-07-23 2020-04-01 Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物

Country Status (11)

Country Link
US (2) US9814753B2 (enExample)
EP (1) EP3024474B1 (enExample)
JP (2) JP2016525548A (enExample)
KR (3) KR20160033220A (enExample)
CN (1) CN105579057A (enExample)
AU (1) AU2014293141A1 (enExample)
CA (1) CA2919198A1 (enExample)
DK (1) DK3024474T3 (enExample)
ES (1) ES2910361T3 (enExample)
MX (1) MX2016001030A (enExample)
WO (1) WO2015013454A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CA2765221C (en) * 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN105579056A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与5-α还原酶抑制剂组合的去氨加压素的方法和组合物
EP3024474B1 (en) 2013-07-23 2022-01-05 Serenity Pharmaceuticals LLC Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
JP2007521244A (ja) * 2003-11-10 2007-08-02 ファイン、シーモア、エイチ． 低用量デスモプレシンを含有する医薬組成物
JP2012513403A (ja) * 2008-12-22 2012-06-14 アラガン，インコーポレイティド 鼻腔内デスモプレシン投与

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
NZ241979A (en) 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP1035833B1 (en) 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
ES2574917T3 (es) 2000-11-30 2016-06-23 Valeritas, Inc. Sistemas y procedimientos de suministro y medición de fluido
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
USRE44872E1 (en) * 2002-11-07 2014-04-29 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP2241326A1 (en) 2003-12-08 2010-10-20 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
CA2633570A1 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
EP2361092A4 (en) 2008-09-04 2012-07-11 Anthony I Rozmanith HEALTH CARE
WO2010075327A1 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Desmopressin composition
CA2765221C (en) * 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
IN2012DN02782A (enExample) * 2009-10-07 2015-09-18 Merck Sharp & Dohme
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
BR112014020271A8 (pt) 2012-03-19 2017-07-11 Wellesley Pharmaceuticals Llc Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
EP3024474B1 (en) 2013-07-23 2022-01-05 Serenity Pharmaceuticals LLC Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
CN105579056A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与5-α还原酶抑制剂组合的去氨加压素的方法和组合物
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007521244A (ja) * 2003-11-10 2007-08-02 ファイン、シーモア、エイチ． 低用量デスモプレシンを含有する医薬組成物
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
JP2012513403A (ja) * 2008-12-22 2012-06-14 アラガン，インコーポレイティド 鼻腔内デスモプレシン投与

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J UROLOGY., 2011, VOL.185, P.219-223, JPN6018008230, ISSN: 0003976004 *
医学のあゆみ, 2011, VOL.238 NO.4, P.329-334, JPN6018008233, ISSN: 0003753078 *
日薬理誌, 2012, VOL.139, P.219-225, JPN6018008232, ISSN: 0003976006 *
調剤と情報, 2013 APR, VOL.19 NO.4, P.108-114, JPN6018008231, ISSN: 0003976005 *

Also Published As

Publication number Publication date
JP7219736B2 (ja) 2023-02-08
ES2910361T3 (es) 2022-05-12
EP3024474A1 (en) 2016-06-01
DK3024474T3 (da) 2022-03-28
US20180289769A1 (en) 2018-10-11
CA2919198A1 (en) 2015-01-29
MX2016001030A (es) 2016-10-07
CN105579057A (zh) 2016-05-11
KR20210103589A (ko) 2021-08-23
KR20240015735A (ko) 2024-02-05
WO2015013454A1 (en) 2015-01-29
EP3024474B1 (en) 2022-01-05
KR20160033220A (ko) 2016-03-25
US20150031613A1 (en) 2015-01-29
US10568927B2 (en) 2020-02-25
JP2020109122A (ja) 2020-07-16
AU2014293141A1 (en) 2016-02-18
US9814753B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
JP7219736B2 (ja) Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
JP2024161452A (ja) アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2022137252A (ja) ５－α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物
EP1397126B1 (en) Use of tramadol for delaying ejaculation

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160406

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191205